Early Feasibility Study of a Novel Male Contraceptive Device: Safety, Usability, and Acceptability Outcomes
This is a Phase 1 feasibility study evaluating the safety, barrier efficacy, and user acceptability of a novel male contraceptive device, the Galactic Cap (GC), an adhesive, polyurethane-based barrier designed to cover the glans penis. Unlike traditional condoms, the device adheres directly to the penile surface to improve fit, reduce slippage, and enhance sensation through increased skin-to-skin contact and improved heat transfer. The study will enroll 40 monogamous heterosexual couples in which the male partner has undergone vasectomy, allowing assessment of device performance independent of pregnancy risk. Participants will use the device during four separate acts of vaginal intercourse over approximately one month, with data collected via genital examinations, participant diaries, post-use surveys, and pre- and post-coital vaginal swabs analyzed for prostate-specific antigen (PSA) to assess semen leakage. The primary objective is to evaluate safety, with secondary assessment of barrier effectiveness and exploratory evaluation of device performance and user satisfaction compared to traditional condoms.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Indiana
-
Carmel、Indiana、美国、46032
- 招聘中
- Indiana University Men's Health Clinic Indiana University Health North Hospital
-
接触:
- Helen Bernie, DO, MPH
- 电话号码:317-688-5500
- 邮箱:hbernie@iu.edu
-
Indianapolis、Indiana、美国、46202
- 招聘中
- Indiana University Men's Health Clinic Indiana University Health North Hospital
-
接触:
- Helen Bernie
- 电话号码:317-688-5500
- 邮箱:hbernie@iu.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:• Heterosexual couples in monogamous stable relationships (>6 months);
- Both male and female participants are required to have >18 years old prior to entering the study;
- Eligible men are those with a prior vasectomy and documented azoospermia on semen analysis prior to the baseline visit;
- Patients must provide a signed and dated informed consent form, indicating their understanding and agreement to participate;
- Patients must be willing to comply with all study procedures and be available for the duration of the study period;
- Both male and female participants are required to have prior experience using a male condom during intercourse;
- All participants (both male and female) must be in good general health based on their medical history and physical examination. At study entry, male participants must have no open penile lesions or lacerations as confirmed by genital exam, and female participants must have no vaginal lesions or lacerations as confirmed by vaginal exam. Participants with significant genital findings at baseline will not be included in this study.
Exclusion Criteria:
-
Participants will be excluded if they do not meet any of the inclusion criteria. Exclusion criteria comprise:
- Couples who are not heterosexual or monogamous;
- Relationships lasting less than six months;
- Individuals under 18 years of age;
- Male participants who have not undergone a prior vasectomy or who do not have a semen analysis confirming azoospermia before the baseline visit;
- Inability or unwillingness to provide signed and dated informed consent;
- Inability to comply with all study procedures;
- Unavailability for the full duration of the study;
- Either partner lacking prior experience with male condom use during intercourse;
- Presence of penile or vaginal lesions or lacerations in either partner, detected during medical physical examination;
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Galactic cap
Increase use of male contraception; Preventing transmission of bodily fluids |
Use galactic cap four times per week for two weeks |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Device Safety
大体时间:Day 1 to Day 30
|
Any potential risk or adverse events associated with device use |
Day 1 to Day 30
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Barrier efficacy
大体时间:Day 7 through day 30
|
Rate of prostate specific antigen (PSA) detection in post coital vaginal samples |
Day 7 through day 30
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 28227
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.